Literature DB >> 11943501

Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny.

Susan E Robinson1.   

Abstract

The effects of exposure to various doses of buprenorphine, methadone or water during the perinatal period were studied on striatal cholinergic development in the rat. Rats were exposed to buprenorphine (0.3 or 3.0 mg/kg/day), methadone (9 mg/kg/day) and/or water prenatally, postnatally or both pre- and postnatally via maternally implanted osmotic minipumps. The effects of buprenorphine varied with the dose used. There were some similarities between the effects of perinatal buprenorphine and perinatal methadone, such as a reduction in striatal acetylcholine (ACh) content in 4-day-old pups exposed prenatally to methadone or buprenorphine (0.3 mg/kg/day). However, differences were also observed between the effects of the two drugs. Unlike methadone, the 0.3-mg/kg/day dose of buprenorphine produced a sex-related increase in striatal ACh in male postnatal day (PND) 21 pups. The 3-mg/kg/day dose of buprenorphine produced a completely different range of results, such as decreased striatal ACh content in 4-day-old pups exposed to the drug postnatally and in 21-day-old pups exposed both pre- and postnatally. Differences in the effects of the two drugs may be related to the different affinities and efficacies of the drugs at different opioid receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943501     DOI: 10.1016/s0892-0362(01)00185-4

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  12 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

Review 2.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

3.  The opioid system and brain development: effects of methadone on the oligodendrocyte lineage and the early stages of myelination.

Authors:  Allison A Vestal-Laborde; Andrew C Eschenroeder; John W Bigbee; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Dev Neurosci       Date:  2014-08-19       Impact factor: 2.984

Review 4.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

Review 6.  Modeling prenatal opioid exposure in animals: Current findings and future directions.

Authors:  Elizabeth M Byrnes; Fair M Vassoler
Journal:  Front Neuroendocrinol       Date:  2017-09-28       Impact factor: 8.606

Review 7.  Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Authors:  Joshua A Berman; David A Talmage; Lorna W Role
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

8.  Opioids affect the fetal brain: reframing the detoxification debate.

Authors:  Steve N Caritis; Ashok Panigrahy
Journal:  Am J Obstet Gynecol       Date:  2019-07-16       Impact factor: 8.661

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

10.  Depression-like effect of prenatal buprenorphine exposure in rats.

Authors:  Chih-Jen Hung; Chih-Cheng Wu; Wen-Ying Chen; Cheng-Yi Chang; Yu-Hsiang Kuan; Hung-Chuan Pan; Su-Lan Liao; Chun-Jung Chen
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.